GlassScriptPhysician profile
Anhthu Thi Bui
NPI 1164994570
$7,270.50
in general payments reported to CMS, 2019-2025
19 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $942 · 2022: $1,497 · 2023: $1,525 · 2024: $1,641 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,735.06 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,559.69 | 2021-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,093.36 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $914.48 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $782.87 | 2022-2025 | |
| Gilead Sciences, INC. | $695.69 | 2021-2025 | Vemlidy |
| Glaxosmithkline, LLC. | $480.79 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $329.02 | 2021-2023 | Veozah |
| Amarin Pharma, INC. | $327.18 | 2021-2022 | |
| Lilly USA, LLC | $309.64 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $227.45 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.25 | 2021-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $77.13 | 2022 | |
| Radius Health, INC. | $67.44 | 2024-2025 | Tymlos |
| Exact Sciences Corporation | $66.99 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $36.01 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $35.36 | 2025 | Aptima |
| Novartis Pharmaceuticals Corporation | $33.05 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $25.79 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anhthu Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.